Can-Fite Completes Phase III Dry Eye Enrollment
Can-Fite, currently traded OTC in the US has filed for a NASDAQ listing.
The company’s subsidiary, OphthaliX Inc., recently announced that it has completed patient enrollment for a Phase
3 clinical study of CF101 for the treatment of Dry Eye Syndrome (DES). The
randomized, double-masked study is conducted in the United States, Europe and
Israel. The study includes 236 patients with moderate-to-severe DES who are
randomized to receive two oral doses of CF101 and a placebo for a period of 24
weeks. The results of this study are expected to be announced in the fourth quarter of
2013.
OphthaliX Inc. is a clinical-stage biopharmaceutical company focused on developing
therapeutic products for the treatment of ophthalmic disorders. OphthaliX’s product
candidate, CF101, is being developed to treat three ophthalmic indications: dry eye
syndrome; glaucoma and uveitis.
CF101, an A3 adenosine receptor agonist, is a novel, first in class, small molecule,
orally bioavailable drug which demonstrated efficacy and an excellent safety profile
in Phase 2 clinical studies. CF101 is currently developed for ophthalmic indications,
including dry eye syndrome (Phase 3), glaucoma (Phase 2) and Uveitis. CF101